Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1

Neoplasia

Volumn 6, Issue 4, 2004, Pages 297-301

  Schenk, Paul W ^a   Stoop, Hans ^a   Bokemeyer, Carsten ^b   Mayer, Frank ^b   Stoter, Gerrit ^a   Oosterhuis, J Wolter ^a   Wiemer, Erik ^a   Looijenga, Leendert H J ^a   Nooter, Kees ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Chemotherapy resistance; Chemotherapy sensitivity; Germ cell tumors; Immunohistochemistry; Protein kinase SRPK1

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PLATINUM DERIVATIVE; PROTEIN KINASE; SERINE ARGININE RICH PROTEIN SPECIFIC KINASE 1; UNCLASSIFIED DRUG; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; GENE CONTROL; GENE EXPRESSION; GENE INACTIVATION; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 3142720339     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.03406     Document Type: Article

References (20)

1. Johnson SW, Ferry KV, and Hamilton TC (1998). Recent insight into platinum drug resistance in cancer. Drug Resist Updates 1, 243-254.
2. Perez RP (1998). Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34, 1535-1542.
3. Niedner H, Christen R, Lin X, Kondo A, and Howell SB (2001). Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60, 1153-1160.
4. Burger H, Capello A, Schenk PW, Stoter G, Brouwer J, and Nooter K (2000). A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin. Biochem Biophys Res Commun 269, 767-774.
5. Schenk PW, Boersma AWM, Brandsma JA, den Dulk H, Burger H, Stoter G, Brouwer J, and Nooter K (2001). SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res 61, 6982-6986.
6. Schenk PW, Boersma AWM, Brok M, Burger H, Stoter G, and Nooter K (2002). Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype. Mol Pharmacol 61, 659-666.
7. Schenk PW, Brok M, Boersma AWM, Brandsma JA, den Dulk H, Burger H, Stoter G, Brouwer J, and Nooter K (2003). Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol 64, 259-268.
8. Bosl GJ and Motzer RJ (1997). Testicular germ cell cancer. N Engl J Med 337, 242-253.
9. Mayer F, Honecker F, Looijenga LHJ, and Bokemeyer C (2003). Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumours. Ann Oncol 14, 825-832.
10. Köberle B, Masters JRW, Hartley JA, and Wood RD (1999). Defective repair of cisplatin-induced damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9, 273-276.
11. Papoutsopoulou S, Nikolakaki E, Chalepakis G, Kruft V, Chevaillier P, and Giannakouros T (1999). SR protein-specific kinase 1 is highly expressed in testis and phosphorylates protamine 1. Nucleic Acids Res 15, 2972-2980.
12. Bokemeyer C, Kollmansberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, and Nichols C (1999). First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumours: a multivariate and matched-pair analysis. J Clin Oncol 17, 3450-3456.
13. Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, and Kanz L (1999). Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17, 512-516.
14. Sanz G, Mir L, and Jacquemin-Sablon A (2002). Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene. Cancer Res 62, 4453-4456.
15. Siebel CW, Feng L, Guthrie C, and Fu XD (1999). Conservation in budding yeast of a kinase specific for SR splicing factors. Proc Natl Acad Sci USA 96, 5440-5445.
16. Oliva R and Dixon GH (1991). Vertebrate protamine genes and the histone-to-protamine replacement reaction. Prog Nucleic Acid Res Mol Biol 40, 25-94.
17. Erez O and Kahana C (2001). Screening for modulators of spermine tolerance identifies Sky1, the SR protein kinase of Saccharomyces cerevisiae, as a regulator of polyamine transport and ion homeostasis. Mol Cell Biol 21, 175-184.
18. Kamachi M, Le TM, Kim SJ, Geiger ME, Anderson P, and Utz PJ (2002). Human autoimmune sera as molecular probes for the identification of an autoantigen kinase signaling pathway. J Exp Med 196, 1213-1225.
19. Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, Bokemeyer C, and Looijenga LHJ (2002). Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62, 2758-7560.
20. Branch P, Hampson R, and Karran P (1995). DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55, 2304-2309.